CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015)
CytomX Therapeutics (CTMX) posted Non-Current Debt of $78000.0 for Q4 2015, down 95.03% on a QoQ basis from $1.6 million in Q4 2014, and down 95.03% year-over-year from $1.6 million in Q4 2014.
CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015) Analysis & Trends
CytomX Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $78000.0 for Q4 2015.
- Quarterly Non-Current Debt fell 95.03% year-over-year to $78000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $78000.0 (down 95.03% YoY) and the FY2015 annual result came in at $78000.0, down 95.03% from the prior year.
- Non-Current Debt was $78000.0 for Q4 2015 at CytomX Therapeutics, down from $1.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.6 million in Q4 2014 and bottomed at $78000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | CytomX Therapeutics | 574.36 Mn | 227.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 78,000.00 |
| Dec 31, 2014 | 1.57 Mn |